Thermoactinoamide A, an Antibiotic Lipophilic Cyclopeptide from the Icelandic Thermophilic Bacterium Thermoactinomyces vulgaris.
Roberta TetaViggó Thór MarteinssonArlette LongeonAlexandra M KlonowskiRené GrobenMarie-Lise Bourguet-KondrackiValeria CostantinoAlfonso MangoniPublished in: Journal of natural products (2017)
The thermophilic bacterium Thermoactinomyces vulgaris strain ISCAR 2354, isolated from a coastal hydrothermal vent in Iceland, was shown to contain thermoactinoamide A (1), a new cyclic hexapeptide composed of mixed d and l amino acids, along with five minor analogues (2-6). The structure of 1 was determined by one- and two-dimensional NMR spectroscopy, high-resolution tandem mass spectrometry, and advanced Marfey's analysis of 1 and of the products of its partial hydrolysis. Thermoactinoamide A inhibited the growth of Staphylococcus aureus ATCC 6538 with an MIC value of 35 μM. On the basis of literature data and this work, cyclic hexapeptides with mixed d/l configurations, one aromatic amino acid residue, and a prevalence of lipophilic residues can be seen as a starting point to define a new, easily accessible scaffold in the search for new antibiotic agents.
Keyphrases
- amino acid
- tandem mass spectrometry
- anaerobic digestion
- high resolution
- ultra high performance liquid chromatography
- high performance liquid chromatography
- staphylococcus aureus
- liquid chromatography
- gas chromatography
- simultaneous determination
- sewage sludge
- solid phase extraction
- mass spectrometry
- municipal solid waste
- systematic review
- climate change
- risk factors
- electronic health record
- molecular docking
- big data
- biofilm formation
- tissue engineering
- human health
- risk assessment
- ms ms